Want to join the conversation?
Steve Scala with Cowen asks about the upcoming KEYTRUDA PDUFA in head and neck cancer, should it be assumed approval will be only for third line PD-L1 positive patients. $MRK said in terms of approval, it cannot be commented what exactly the label will look like.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!
$SGY is expected to achieve $6.17 price target in next year, with a minimum target of $3.00, due to the price increase of 27.85% to $6.29 during the last trading session.
$SWHC showing consistent increase in sales for the past three quarters suggesting the US craze for firearms is not going to subside soon.